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How can you prevent migraines
during pregnancy?
z Evidence summary
Eighteen percent of all women report
migraines.1 Among pregnant migraineurs,
2.5% to 8% reported worsening symp-
toms.1,2 Guidelines recommend considering
prophylaxis for nonpregnant patients if
they experience at least 3 or 4 prolonged
severe attacks per month.3
Nonpharmacological treatment. Two
studies were published together evaluating
thermal biofeedback, relaxation training,
and physical therapy exercises. The first, a
cohort study, showed alleviation of symp-
toms for 15 of 19 women. The second, a
No randomized controlled trials (RCT) have
addressed pharmacologic prophylaxis of
migraine for pregnant women. Two studies
suggest that nonpharmacologic therapies
(combinations of skin warming, relaxation,
biofeedback, and physical therapy) not 
only relieved acute pain, but also decreased
the frequency of headaches (strength of
recommendation [SOR]: B, poor-quality
cohort and RCTs).
Practice guidelines and most review 
articles recommend avoiding prophylactic
medications if possible. If a medication
must be used, base the selection on 
both effectiveness for nonpregnant patients
and established pregnancy safety from 
surveillance studies (SOR: C, expert 
opinion).
Nonpharmacologic approaches, limited
analgesics remain the mainstay 
of prevention for pregnant women
Standards of care favor minimizing any use
of drugs with known or even theoretical risk
to the fetus. That includes virtually all the
classes of drugs prescribed for migraine
prevention. Limited use of analgesics 
such as acetaminophen and opioids for
migraine-abortive treatment is closer to the
standard of care for severe headaches. The
nonpharmacologic approaches delineated
in this article are the mainstay of treatment.
Prophylactic pharmacotherapy for
migraine would be more justifiable if it also
treated other conditions in which the
risks/benefits for both the mother and fetus
were clearer, such as maternal hypertension
(in which labetalol can be effective for both
conditions), or severe depression. Other
nontraditional therapies that have shown
efficacy for nonpregnant patients such as
magnesium supplementation may be 
worthy of study since the risk of fetal harm
in all trimesters appears remote.
In all cases, carefully documenting patient
involvement in risk/benefit discussions.
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Nonpharmacologic
approaches are
the mainstay 
of prevention—
skin warming,
relaxation training,
biofeedback, and
physical therapy
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small unblinded RCT, compared 11
women using the combination treatment
with 14 control women who received
attention from the therapist but no other
intervention. Over 72% of the treatment
arm improved compared with nearly 29%
of the control group.4 The 30 women (19
from the original cohort and the 11 from
the intervention arm of the RCT) were
then followed as a cohort for the duration
of pregnancy and 1 year postpartum.
More than 67% of the patients continued
to report a decrease in the frequency and
severity of headache.5 Interpretation of
these studies is limited by small sample 
size and testing in settings with specialized
resources that are not found in every
community.
Pharmacologic agents. Randomized
controlled trials have demonstrated that
multiple medications have prophylactic
benefit in the treatment of nonpregnant
patients with migraine. In particular,
propanolol,6 divalproex sodium/sodium
valproate, and topiramate7 have been
effective. A single case report on the use of
labetalol by a pregnant woman at 28
weeks’ gestational age showed that it was
effective in reducing the frequency and
severity of her headaches after 1 week of
use. This improvement persisted until
delivery at 38 weeks.8
Safety in pregnancy. The Food and
Drug Administration (FDA) assigns fetal
risk categories to all drugs based on con-
trolled studies in humans, animal reproduc-
tion studies, and surveillance studies.9
There are no data about the effectiveness of
medications for migraine prophylaxis in
pregnancy so one cannot select a specific
medication with certainty. However, it may
be reasonable to select medications based
on both effectiveness for nonpregnant
patients and established safety as deter-
mined by the FDA’s fetal risk summary. 
The TABLE shows commonly used
drugs for prophylaxis of migraine and
their pregnancy risk category classifica-
tion. It should be noted that even if risk has
been demonstrated in a medication, not all
risks are equal. For example, propanolol is
class D because of increased risk for
intrauterine growth restriction in the third
trimester, while sodium valproate is class D
because of known teratogenicity.9
Recommendations from others
Practice guidelines published by the
American Academy of Neurology recom-
mend avoidance of prophylactic medica-
tions in pregnancy, if possible. They also
recommend nonpharmacologic treatment
as an acceptable option in pregnancy. If
drug treatment is necessary, they recom-
mend selecting an agent with the lowest
risk of adverse effects to the fetus.3 Most
review articles state that, if medication is
necessary, it should be tailored towards
other comorbidities, if possible; if there
are no coexisting conditions, then calci-
um channel blockers or beta blockers
would be the treatment of choice, based
on safety data.1,10
TA B L E
MEDICATION PREGNANCY RISK CATEGORY
Labetalol (Normodyne, Trandate) C/D*
Propanolol (Inderal, Inderide) C/D*
Verapamil (Calan, Isoptin, Verelan) C
Nifedipine (Procardia) C
Amitriptyline (Limbitrol) C
Nortriptyline (Aventyl, Pamelor) D
Fluoxetine (Prozac) C 
Gabapentin (Neurontin) C
Divalproex sodium (Depakote) D
Topiramate (Topamax) C
A=Controlled human studies show no risk, B=No evidence of risk in humans, but no 
controlled studies, C=Risk to humans has not been ruled out, D=Positive evidence of 
risk to humans from human or animal studies, X=Contraindicated in pregnancy.
*Category changes to D if used in 3rd trimester.
Source: Briggs et al 2002.9
Pregnancy risk category 
of some prophylactic drugs for migraine
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